|
Ponatinib Clinical Trials
7 actively recruiting trials across 4 locations
Also known as: AP 24534, AP-24534, AP24534, Iclusig, Iclusig, INCB84344
Pipeline
Phase 2: 4Phase 1/2: 2
Top Sponsors
- University of Chicago2
- University of Washington1
- Peking University People's Hospital1
- National Cancer Institute (NCI)1
- M.D. Anderson Cancer Center1
Indications
- Cancer7
- Acute Lymphoblastic Leukemia3
- Lymphoblastic Leukemia2
- Lymphoblastic Lymphoma2
- B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL11
Other2 trials
Chicago, Illinois2 trials
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago Medicine Comprehensive Cancer Center
Phase 1/2
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago Medical Center
Phase 2
Birmingham, Alabama1 trial
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
University of Alabama at Birmingham Cancer Center
Phase 2
Houston, Texas1 trial
Seattle, Washington1 trial
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.